Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Konstantinos Kostikas, Katerina Dimakou, Konstantinos Gourgoulianis, Mina Gaga, Dimosthenis Papapetrou, Georgios Tsoukalas, Panagiotis Chatziapostolou, Antonios Antoniadis, Georgios Meletis, Efstathia Evangelopoulou, Panagiota Styliara, Ilektra Karypidou, Athena Gogali, Konstantinos Kalafatakis & Nikolaos Tzanakis. (2022) A Real-World Study on the Day and Night-Time Symptoms Among Greek COPD Patients Who Recently Initiated Treatment with Dual Bronchodilation: The DANICO Study. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 2027-2041.
Read now
Read now
Anthony D. D’Urzo, Dave Singh, James F. Donohue, Kenneth R. Chapman & Robert A. Wise. (2021) Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update. Expert Review of Respiratory Medicine 15:9, pages 1093-1106.
Read now
Read now
Donald P Tashkin. (2020) Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 3105-3122.
Read now
Read now
Anthony D D’Urzo, Dave Singh, James F Donohue, Edward M Kerwin, Anna Ribera, Eduard Molins, Ferran Chuecos, Diana Jarreta & Esther Garcia Gil. (2019) Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 479-491.
Read now
Read now
Mario Malerba, Alessandro Radaeli, Giuseppe Santini, Jaymin Morjaria, Nadia Mores, Chiara Mondino, Giuseppe Macis & Paolo Montuschi. (2018) The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Discovery 13:6, pages 563-577.
Read now
Read now
Mònica Monteagudo, Montse Roset, Teresa Rodriguez-Blanco, Laura Muñoz & Marc Miravitlles. (2017) Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1145-1152.
Read now
Read now
Articles from other publishers (12)
Jiangang Ju, Zheming Li & Qiang Shi. (2022) Baicalin Inhibits Inflammation in Rats with Chronic Obstructive Pulmonary Disease by the TLR2/MYD88/NF-κBp65 Signaling Pathway. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-11.
Crossref
Crossref
Maria Montes de Oca1, Maria Victorina Lopez Varela2, Ana Maria B. Menezes3, Fernando C. Wehrmeister3, Larissa Ramirez4 & Marc Miravitlles5. (2021) Respiratory symptoms (COPD Assessment Test and modified Medical Research Council dyspnea scores) and GOLD-ABCD COPD classification: the LASSYC study. Jornal Brasileiro de Pneumologia, pages e20210156.
Crossref
Crossref
Ioanna Tsiligianni & Janwillem W. H. Kocks. (2020) Daytime symptoms of chronic obstructive pulmonary disease: a systematic review. npj Primary Care Respiratory Medicine 30:1.
Crossref
Crossref
S N Avdeev & N V Trushenko. (2019) New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease. Terapevticheskii arkhiv 91:3, pages 76-85.
Crossref
Crossref
Usman Maqsood, Terence N Ho, Karen Palmer, Fiona JR Eccles, Mohammed Munavvar, Ran Wang, Iain Crossingham & David JW Evans. (2019) Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2019:3.
Crossref
Crossref
Anthony D. D’Urzo, Dave Singh, James F. Donohue & Kenneth R. Chapman. (2019) Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. Therapeutic Advances in Respiratory Disease 13, pages 175346661985072.
Crossref
Crossref
Han Ni, Soe Moe, Zay Soe, Kay Thi Myint & K Neelakantan Viswanathan. (2018) Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
A. A. Vizel & I. Yu. Vizel. (2018) 12-Hour fixed-dose combination of andrenergic agonist and cholinergic antagonist in a new administration device: analytical review. Medical Council:15, pages 116-122.
Crossref
Crossref
Steven D. Deas & Nikhil Huprikar. (2018) Dual bronchodilator therapy for chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 24:2, pages 130-137.
Crossref
Crossref
Marc Miravitlles, Ana Menezes, Maria Victorina López Varela, Alejandro Casas, Luis Ugalde, Alejandra Ramirez-Venegas, Laura Mendoza, Ana López, Fernando C. Wehrmeister, Filip Surmont & Maria Montes de Oca. (2018) Prevalence and impact of respiratory symptoms in a population of patients with COPD in Latin America: The LASSYC observational study. Respiratory Medicine 134, pages 62-69.
Crossref
Crossref
Pengpeng Zhang, Xiaofeng Xin, Liping Fang, Hao Jiang, Xiaoyong Xu, Xin Su & Yi Shi. (2017) HMGB1 mediates Aspergillus fumigatus -induced inflammatory response in alveolar macrophages of COPD mice via activating MyD88/NF-κB and syk/PI3K signalings. International Immunopharmacology 53, pages 125-132.
Crossref
Crossref
Frederico Leon Arrabal Fernandes, Alberto Cukier, Aquiles Assunção Camelier, Carlos Cezar Fritscher, Cláudia Henrique da Costa, Eanes Delgado Barros Pereira, Irma Godoy, José Eduardo Delfini Cançado, José Gustavo Romaldini, Jose Miguel Chatkin, José Roberto Jardim, Marcelo Fouad Rabahi, Maria Cecília Nieves Maiorano de Nucci, Maria da Penha Uchoa Sales, Maria Vera Cruz de Oliveira Castellano, Miguel Abidon Aidé, Paulo José Zimermann Teixeira, Renato Maciel, Ricardo de Amorim Corrêa, Roberto Stirbulov, Rodrigo Abensur Athanazio, Rodrigo Russo, Suzana Tanni Minamoto & Fernando Luiz Cavalcanti Lundgren. (2017) Recommendations for the pharmacological treatment of COPD: questions and answers. Jornal Brasileiro de Pneumologia 43:4, pages 290-301.
Crossref
Crossref